This Covid-19 testing specialist has been a major winner from the pandemic. With the shares up over 12,000% in the past 12 months, can they really still be considered good value, as some contend? Our research into the phenomena that is Novacyt reflects on the facts, opportunities and risks.
Novacyt SA (LON:NCTR, PAR:ALNOV) is an international diagnostics group involved in the sale of diagnostic and pathogen testing kits based on molecular and protein testing technologies. We have followed the stock with interest in our regular Coronavirus updates, since February 2020 when we commented on Novacyt’s big break.
While its main activities are principally based in the UK, the holding company is incorporated in France and ‘listed’ on AIM and Euronext Growth Paris stock markets. For…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login
Previous article
Next article
More on Novacyt SA
02/02/2021 · Company Insights
After a volatile start to 2021, the share price of last year’s top AIM performer received…
29/01/2021 · Company Insights
AIM’s top performer from 2020 announces fabulous numbers, but that was last year, what of the…
More Company Insights
It’s looking more encouraging for the much-maligned WPP
01/03/2021
Great to see these small companies accelerating investment
26/02/2021
The first in our new series covering fast-growing small caps
More on Novacyt SA
More Company Insights